Title |
Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
|
---|---|
Published in |
Journal of Translational Medicine, April 2013
|
DOI | 10.1186/1479-5876-11-97 |
Pubmed ID | |
Authors |
Hiroyuki Suzuki, Mitsuro Fukuhara, Takumi Yamaura, Satoshi Mutoh, Naoyuki Okabe, Hiroshi Yaginuma, Takeo Hasegawa, Atsushi Yonechi, Jun Osugi, Mika Hoshino, Takashi Kimura, Mitsunori Higuchi, Yutaka Shio, Kazuya Ise, Kazuyoshi Takeda, Mitsukazu Gotoh |
Abstract |
BACKGROUND: Vaccine treatment using multiple peptides derived from multiple proteins is considered to be a promising option for cancer immune therapy, but scientific evidence supporting the therapeutic efficacy of multiple peptides is limited. METHODS: We conducted phase I trials using a mixture of multiple therapeutic peptide vaccines to evaluate their safety, immunogenicity and clinical response in patients with advanced/recurrent NSCLC. We administered two different combinations of four HLA-A24-restricted peptides. Two were peptides derived from vascular endothelial growth factor receptor 1 (VEGFR1) and 2 (VEGFR2), and the third was a peptide derived from up-regulated lung cancer 10 (URLC10, which is also called lymphocyte antigen 6 complex locus K [LY6K]). The fourth peptide used was derived from TTK protein kinase (TTK) or cell division associated 1 (CDCA1). Vaccines were administered weekly by subcutaneous injection into the axillary region of patients with montanide ISA-51 incomplete Freund's adjuvant, until the disease was judged to have progressed or patients requested to be withdrawn from the trial. Immunological responses were primarily evaluated using an IFN-gamma ELiSPOT assay. RESULTS: Vaccinations were well tolerated with no severe treatment-associated adverse events except for the reactions that occurred at the injection sites. Peptide-specific T cell responses against at least one peptide were observed in 13 of the 15 patients enrolled. Although no patient exhibited complete or partial responses, seven patients (47%) had stable disease for at least 2 months. The median overall survival time was 398 days, and the 1- and 2-year survival rates were 58.3% and 32.8%, respectively. CONCLUSION: Peptide vaccine therapy using a mixture of four novel peptides was found to be safe, and is expected to induce strong specific T cell responses.Trial registration: These studies were registered with ClinicalTrials.gov NCT00633724 and NCT00874588. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Members of the public | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Denmark | 1 | 1% |
Unknown | 81 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 21 | 26% |
Student > Ph. D. Student | 12 | 15% |
Other | 8 | 10% |
Student > Bachelor | 5 | 6% |
Student > Master | 5 | 6% |
Other | 10 | 12% |
Unknown | 21 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 19 | 23% |
Agricultural and Biological Sciences | 10 | 12% |
Biochemistry, Genetics and Molecular Biology | 8 | 10% |
Immunology and Microbiology | 8 | 10% |
Chemistry | 2 | 2% |
Other | 12 | 15% |
Unknown | 23 | 28% |